Zohar Bassevitch

TL;DR: The COLCORONA trial as mentioned in this paper investigated the effect of colchicine on the composite of COVID-19-related death or hospital admission and found that colchics led to a lower rate of the composite adverse events than placebo.

TL;DR: A randomized, double-blind trial involving non-hospitalized patients with COVID-19 diagnosed by polymerase chain reaction (PCR) testing or clinical criteria was performed in this article.

TL;DR: This article conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial and found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10-8) near the natriuretic peptide receptor 3 gene.

TL;DR: The authors conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial and found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10−8) near the natriuretic peptide receptor 3 gene.